JP2008524167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008524167A5 JP2008524167A5 JP2007546073A JP2007546073A JP2008524167A5 JP 2008524167 A5 JP2008524167 A5 JP 2008524167A5 JP 2007546073 A JP2007546073 A JP 2007546073A JP 2007546073 A JP2007546073 A JP 2007546073A JP 2008524167 A5 JP2008524167 A5 JP 2008524167A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- pro
- gly
- mimetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 9
- 229940024606 amino acid Drugs 0.000 claims 8
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical compound NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 claims 8
- 125000006850 spacer group Chemical group 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 7
- 239000000126 substance Chemical group 0.000 claims 6
- 239000004475 Arginine Substances 0.000 claims 5
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims 5
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 5
- 235000009697 arginine Nutrition 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- KEZRWUUMKVVUPT-UHFFFAOYSA-N 4-azaleucine Chemical compound CN(C)CC(N)C(O)=O KEZRWUUMKVVUPT-UHFFFAOYSA-N 0.000 claims 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 3
- 125000001099 N(omega)-arginino group Chemical group 0.000 claims 3
- ASAGJJCSLOPYTP-UHFFFAOYSA-N amino(propan-2-yl)carbamic acid Chemical compound CC(C)N(N)C(O)=O ASAGJJCSLOPYTP-UHFFFAOYSA-N 0.000 claims 3
- 229960002429 proline Drugs 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims 2
- 229930182831 D-valine Natural products 0.000 claims 2
- 229930195710 D‐cysteine Natural products 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 235000013878 L-cysteine Nutrition 0.000 claims 2
- 239000004201 L-cysteine Substances 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 230000000923 atherogenic effect Effects 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 150000003141 primary amines Chemical group 0.000 claims 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 2
- 229960004295 valine Drugs 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims 1
- 229930028154 D-arginine Natural products 0.000 claims 1
- 229930182846 D-asparagine Natural products 0.000 claims 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 1
- 229930195721 D-histidine Natural products 0.000 claims 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims 1
- 229930182819 D-leucine Natural products 0.000 claims 1
- 229930182820 D-proline Natural products 0.000 claims 1
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 claims 1
- 229930182822 D-threonine Natural products 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- 235000019454 L-leucine Nutrition 0.000 claims 1
- 239000004395 L-leucine Substances 0.000 claims 1
- 229930182821 L-proline Natural products 0.000 claims 1
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108010077895 Sarcosine Proteins 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 229960005261 aspartic acid Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 238000006664 bond formation reaction Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 150000003140 primary amides Chemical group 0.000 claims 1
- 108010029020 prolylglycine Proteins 0.000 claims 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940043230 sarcosine Drugs 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960002898 threonine Drugs 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 206010047470 viral myocarditis Diseases 0.000 claims 1
- IDSBGYJDXUBNFY-GCNCJWNFSA-N CC(C)[C@@H](C(N[C@@H](C(C)C)C(N(CCC1)[C@]1(CCN1CC(N)=O)C1=O)=O)=O)NC([C@H](CC(O)=O)NC(c1cnccc1)=O)=O Chemical compound CC(C)[C@@H](C(N[C@@H](C(C)C)C(N(CCC1)[C@]1(CCN1CC(N)=O)C1=O)=O)=O)NC([C@H](CC(O)=O)NC(c1cnccc1)=O)=O IDSBGYJDXUBNFY-GCNCJWNFSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04425929 | 2004-12-20 | ||
| PCT/EP2005/056847 WO2006067091A1 (en) | 2004-12-20 | 2005-12-16 | Myd88 homodimerization inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008524167A JP2008524167A (ja) | 2008-07-10 |
| JP2008524167A5 true JP2008524167A5 (enExample) | 2009-02-12 |
Family
ID=34932941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007546073A Withdrawn JP2008524167A (ja) | 2004-12-20 | 2005-12-16 | ＭｙＤ８８ホモ二量体化阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080064643A1 (enExample) |
| EP (1) | EP1828246A1 (enExample) |
| JP (1) | JP2008524167A (enExample) |
| KR (1) | KR20070094802A (enExample) |
| CN (1) | CN101084240A (enExample) |
| AU (1) | AU2005318226A1 (enExample) |
| BR (1) | BRPI0519148A2 (enExample) |
| CA (1) | CA2590750A1 (enExample) |
| MX (1) | MX2007007259A (enExample) |
| WO (1) | WO2006067091A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0323204D0 (en) * | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| CN101745094A (zh) * | 2010-01-28 | 2010-06-23 | 华中科技大学同济医学院附属同济医院 | MyD88拓扑类肽化合物作为免疫抑制剂在医学上的用途 |
| WO2012047175A1 (en) | 2010-10-05 | 2012-04-12 | Kemijski inštitut | Fusion polypeptides comprising tir and dimerization domain for modulation of tlr/innate immunity signaling |
| CN102336720B (zh) | 2011-03-02 | 2016-01-13 | 华中科技大学 | 2-氨基噻唑衍生物及制备方法和应用 |
| US10465247B2 (en) | 2011-07-01 | 2019-11-05 | Dana-Farber Cancer Institute, Inc. | Discovery of a somatic mutation in MYD88 gene in lymphoplasmacytic lymphoma |
| PT3366302T (pt) * | 2011-07-18 | 2022-03-07 | Univ Kentucky Res Found | Proteção de células da degeneração induzida por rna alu e inibidores para proteger as células |
| EP2561873A1 (de) * | 2011-08-26 | 2013-02-27 | Forschungsverbund Berlin e.V. | Strukturmimetika prolinreicher Peptide und ihre Verwendung |
| US9707235B1 (en) | 2012-01-13 | 2017-07-18 | University Of Kentucky Research Foundation | Protection of cells from degeneration and treatment of geographic atrophy |
| WO2013112834A1 (en) * | 2012-01-25 | 2013-08-01 | Vanderbilt University | Compositions and methods for treating infections |
| WO2013169382A1 (en) | 2012-05-07 | 2013-11-14 | DePuy Synthes Products, LLC | Methods and devices for treating intervertebral disc disease |
| EP2920197B1 (en) * | 2012-09-26 | 2021-03-17 | President and Fellows of Harvard College | Proline-locked stapled peptides and uses thereof |
| WO2015038887A1 (en) | 2013-09-12 | 2015-03-19 | Dana-Farber Cancer Institute Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| WO2015085075A1 (en) | 2013-12-06 | 2015-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance |
| AU2014361798B2 (en) | 2013-12-13 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3230300B1 (de) | 2014-12-11 | 2021-11-24 | Forschungsverbund Berlin E.V. | Inhibitoren zur hemmung der tumormetastasierung |
| JP2019069905A (ja) * | 2016-02-29 | 2019-05-09 | 国立大学法人大阪大学 | 組織損傷治療剤 |
| JP2019518006A (ja) | 2016-04-29 | 2019-06-27 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ |
| EP3464325A1 (en) | 2016-06-07 | 2019-04-10 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Backbone cyclized inhibitory peptides of myeloid differentiation factor 88 (myd88) |
| KR20200064075A (ko) | 2017-09-07 | 2020-06-05 | 포그 파마슈티컬스 인코포레이티드 | 베타-카테닌 기능을 조절하는 제제 및 이의 방법 |
| CN112153897B (zh) * | 2018-01-02 | 2023-02-03 | 拉什大学医学中心 | 用于治疗神经病学和其他病症的组合物和方法 |
| WO2024096677A1 (ko) * | 2022-11-03 | 2024-05-10 | 한국과학기술연구원 | Tlr 신호 억제 펩타이드 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2446458A1 (en) | 2001-05-09 | 2002-11-14 | Yale University | Toll/interleukin-1 receptor adaptor protein (tirap) |
| AU2002366331A1 (en) * | 2001-12-17 | 2003-06-30 | Cedars-Sinai Medical Center | Treating vascular disease by inhibiting myeloid differentiation factor 88 |
-
2005
- 2005-12-16 CA CA002590750A patent/CA2590750A1/en not_active Abandoned
- 2005-12-16 CN CNA2005800437629A patent/CN101084240A/zh active Pending
- 2005-12-16 US US11/793,516 patent/US20080064643A1/en not_active Abandoned
- 2005-12-16 BR BRPI0519148-3A patent/BRPI0519148A2/pt not_active IP Right Cessation
- 2005-12-16 EP EP05823931A patent/EP1828246A1/en not_active Withdrawn
- 2005-12-16 JP JP2007546073A patent/JP2008524167A/ja not_active Withdrawn
- 2005-12-16 AU AU2005318226A patent/AU2005318226A1/en not_active Abandoned
- 2005-12-16 MX MX2007007259A patent/MX2007007259A/es not_active Application Discontinuation
- 2005-12-16 KR KR1020077016815A patent/KR20070094802A/ko not_active Withdrawn
- 2005-12-16 WO PCT/EP2005/056847 patent/WO2006067091A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008524167A5 (enExample) | ||
| CA1339793C (en) | Cyclic analogs of atrial natriuretic peptides | |
| US5618914A (en) | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same | |
| Appell et al. | Antagonists that demonstrate species differences in neurokinin-1 receptors. | |
| US20230406884A1 (en) | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | |
| JPWO2020175473A1 (ja) | ペプチド化合物の製造方法、保護基形成用試薬、及び、芳香族複素環化合物 | |
| CN102105485B (zh) | 选择性胱天蛋白酶抑制剂及其用途 | |
| US20050267017A1 (en) | Conformationally constrained C-backbone cyclic peptides | |
| KR970009887B1 (ko) | 심방의 나트륨이뇨성 펩티드의 선형유사체 | |
| Melander et al. | Discrimination of A/T sequences in the minor groove of DNA within a cyclic polyamide motif | |
| JP2008524167A (ja) | ＭｙＤ８８ホモ二量体化阻害剤 | |
| AU627156B2 (en) | Amino acid derivatives | |
| JP2022532069A (ja) | Ｍａｓｐ阻害化合物およびその使用 | |
| US20120116027A1 (en) | Process for the purification of human growth hormone polypeptides using affinity resins comprising specific ligands | |
| US20240317796A1 (en) | Method for producing peptide compound, protective group-forming reagent, and substituted benzyl compound | |
| JP5689892B2 (ja) | ２−アミノ−３−メチル−ヘキサ−５エン酸、及びバシトラシン等のペプチドの生成におけるその使用方法 | |
| KR100375421B1 (ko) | 항암효과를갖는파네실전이효소저해제 | |
| JP5223162B2 (ja) | ペプチド又は蛋白質標識用の蛍光色素、及び該蛍光色素を利用した標識方法 | |
| Rodrigues et al. | Synthesis and conformational investigation of tetrapeptide analogues of the fragment B23-B26 of insulin | |
| US5686565A (en) | Bradykinin antagonist pseudopeptide derivatives of aminoalkanoic acids and related olefins | |
| JP2008517016A5 (enExample) | ||
| UA94226C2 (ru) | Пептидные токсины как терапевтические средства | |
| JP4643156B2 (ja) | Ｎ−アシルスルホンアミド結合を有する新規ホスミドシン類縁体 | |
| JPH06501961A (ja) | 免疫調節活性を有するシユードペンタペプチド | |
| TW202440615A (zh) | 介白素－２３受體之肽抑制劑 |